ALFA Finder
20:34 IST
NSE
Earnings Call
Zim Laboratories Investor Presentation: Key Takeaways
Q2 FY27 operating income ₹1,054 Mn (+18.9% YoY), EBITDA ₹77 Mn at 7.3% margin, PAT loss ₹21 Mn. EU-GMP cost base weighs on margins.
Zim Laboratories Ltd
- Share price
- ₹134.66
- Market cap
- ₹722.6 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 348.8×Sector 43.8×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Employee Stock Options 6Merger & Restructuring 5Earnings Call 5Annual General Meeting 5Financial Results 4Board Meeting Date 3Regulatory Approval 2Promoter Buying (Off-Market) 2Other Announcement 2Management Change 1Credit Rating 1Business Update 1Annual Report 1Acquisition 1
Time
5 announcements with these filters
19:20 IST
BSE
Earnings Call
Zim Laboratories Investor Presentation: Key Takeaways
Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.
- Call
- Guides 32% growth
19:10 IST
NSE
Earnings Call
Zim Laboratories Investor Presentation: Key Takeaways
Q1 FY27 Total Operating Income rose 31.2% YoY to ₹942 Mn. However, EBITDA fell 40% to ₹34 Mn due to utility/employee costs.
15:54 IST
NSE
Earnings Call
Zim Laboratories Earnings Call: Key Takeaways
Zim Laboratories reported FY26 revenue of ₹3,744M, flat YoY, impacted by geopolitical issues in the MENA region and EU GMP constraints. Strategy focuses on remediation and transitioning from R&D to execution.
19:15 IST
NSE
Earnings Call
Zim Laboratories Earnings Call: Key Takeaways
Zim Laboratories reported FY26 revenue of ₹3,744 Mn with 11.1% EBITDA margin. Strategy shifts towards innovative products (NIP/OTF) despite regulatory headwinds and geopolitical logistics challenges.